Dimiter V Tassev

US Patent:

20140024809, Jan 23, 2014

Filed:

Feb 13, 2012

Appl. No.:

13/984646

Inventors:

Dimiter Tassev - Chicago IL, US
Jian Hu - Forest Hills NY, US

Assignee:

MEMORIAL SLOAN-KETTERING CANCER CENTER - New York NY

International Classification:

C07K 16/28

US Classification:

5303873, 5303879, 5303917

Abstract:

Antigen binding proteins with TCR-like paratopes, that is, with an antigen binding region specific for an HLA-A2 restricted peptide are disclosed. The antigen binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, Fab fragments, F(ab′)2 fragments, and single chain Fv fragments. Fusion proteins, such as scFv fusions with immunoglobulin or T-cell receptor domains, incorporating the specificity of the antigen binding region for each peptide are also contemplated by the invention. Furthermore, immunoconjugates may include antibodies to which is linked a radioisotope, fluorescent or other detectable marker, cytotoxin, or other molecule are also encompassed by the invention. Among other things, immunoconjugates can be used for delivery of an agent to elicit a therapeutic effect or to facilitate an immune effector function.

US Patent:

20160152725, Jun 2, 2016

Filed:

Feb 25, 2015

Appl. No.:

14/631211

Inventors:

- New York NY, US
Mahiuddin Ahmed - New York NY, US
Richard J. O'Reilly - Roxbury CT, US
Dimiter V. Tassev - New York NY, US
Qi Zhao - Hong Kong, CN

International Classification:

C07K 16/32
C07K 16/30
A61K 51/10
C07K 16/46
A61K 47/48
A61K 49/00
C07K 16/28
C07K 14/725

Abstract:

Antigen-binding proteins specific for HLA-A2-restricted Wilms tumor 1 peptide are disclosed. The antigen-binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, Fab fragments, F(ab′)2 fragments, and single chain Fv (scFv) fragments, as well as chimeric antigen receptors. Fusion proteins, such as scFv fusions with immunoglobulin or T-cell receptor domains, incorporating the antigen-binding proteins are provided. Methods of using the antigen-binding proteins in the treatment of hyperproliferative diseases such as cancer are also disclosed.

US Patent:

20150322154, Nov 12, 2015

Filed:

Apr 16, 2015

Appl. No.:

14/688355

Inventors:

- New York NY, US
Dimiter V. Tassev - New York NY, US
Jian Hu - Forest Hills NY, US

International Classification:

C07K 16/28

Abstract:

Antigen binding proteins with TCR-like paratopes, that is, with an antigen binding region specific for an HLA-A2 restricted peptide are disclosed. The antigen binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, Fab fragments, F(ab′)2 fragments, and single chain Fv fragments. Fusion proteins, such as scFv fusions with immunoglobulin or T-cell receptor domains, incorporating the specificity of the antigen binding region for each peptide are also contemplated by the invention. Furthermore, immunoconjugates may include antibodies to which is linked a radioisotope, fluorescent or other detectable marker, cytotoxin, or other molecule are also encompassed by the invention. Among other things, immunoconjugates can be used for delivery of an agent to elicit a therapeutic effect or to facilitate an immune effector function.

US Patent:

20140296492, Oct 2, 2014

Filed:

Jun 9, 2014

Appl. No.:

14/299509

Inventors:

Nai-Kong CHEUNG - Purchase NY, US
Dimiter Tassev - Chicago IL, US
Jian Hu - Forest Hills NY, US

Assignee:

Memorial Sloan-Kettering Cancer Center - New York NY

International Classification:

C07K 16/28

US Classification:

5303873, 5303879, 5303917

Abstract:

Antigen binding proteins with TCR-like paratopes, that is, with an antigen binding region specific for an HLA-A2 restricted peptide are disclosed. The antigen binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, Fab fragments, F(ab′)2 fragments, and single chain Fv fragments. Fusion proteins, such as scFv fusions with immunoglobulin or T-cell receptor domains, incorporating the specificity of the antigen binding region for each peptide are also contemplated by the invention. Furthermore, immunoconjugates may include antibodies to which is linked a radioisotope, fluorescent or other detectable marker, cytotoxin, or other molecule are also encompassed by the invention. Among other things, immunoconjugates can be used for delivery of an agent to elicit a therapeutic effect or to facilitate an immune effector function.